整个大脑体积的损失与无复发性多发性硬化症的短期残疾进展有关
Roland Opfer1, Lothar Spies1, Julia Krüger1
1jung diagnostics GmbH, Hamburg, Germany.
Journal of neurology
|October 21, 2025
概括
在多发性硬化症 (MS) 中,大脑体积损失 (BVL) 是独立于复发活动 (PIRA) 的残疾进展的可靠指标. 这种MRI生物标志物可以预测症状恶化,即使没有复发或新的病变.
科学领域:
- 神经学 神经学
- 放射学 放射学是一门学科.
- 生物标志物研究 生物标志物研究
背景情况:
- 多发性硬化症 (MS) 需要可靠的生物标志物来确定残疾进展是否独立于复发活动 (PIRA).
- 目前的常规患者护理缺乏PIRA的验证标志物.
- 这项研究调查了MS中PIRA的脑MRI生物标志物.
研究的目的:
- 在MS患者中调查大脑MRI生物标志物和PIRA变化之间的关联.
- 确定可靠的短期风险标志物,用于MS中残疾进展.
主要方法:
- 一项前性,观察性,多中心研究,涉及453名复发性复发性多发性硬化症患者.
- 基线和一年的随访MRI (3D-T1,2D/3D-FLAIR) 评估大脑体积损失 (BVL) 和新的/扩大的T2损伤.
- 相关性和后勤回归分析以评估EDSS进展和BVL/年之间的关联.
主要成果:
- 大脑体积损失 (BVL) /年与扩展残疾状态量表 (EDSS) 进展有显著的相关性 (r = -0.14,p = 0.002).
- 即使在没有复发或新病变的患者中,这种关联仍然显著 (r = -0.17,p = 0.008).
- BVL/年是EDSS进展的显著预测因素 (p<0.001),BVL/年下降0.5%的相对风险增加26%.
结论:
- 一年内大脑体积损失 (BVL) 与多发性硬化症EDSS进展显著相关.
- BVL是残疾进展的有价值的短期风险标志物,独立于复发或新病变.
- 这些发现支持使用BVL作为MS中PIRA的常规患者护理生物标志物.
相关概念视频
Multiple Sclerosis l: Introduction
31
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
31
Cerebral Edema ll: Pathophysiology
31
Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this...
31


